Liberate Bio Harnesses Platinum Protein Sequencing Technology to Accelerate Genetic Medicine Discoveries

In a strategic technology integration, Liberate Bio—a Boston-headquartered biotech company pioneering novel delivery vehicles for genetic medicines—has adopted Quantum-Si’s Platinum Next-Generation Protein Sequencer (NGPS) to enhance their therapeutic development pipeline. This collaboration demonstrates how advanced protein sequencing capabilities are reshaping the landscape of precision gene therapy research.

Transforming Gene Therapy Development Through Protein Barcoding

The integration centers on Quantum-Si’s protein barcoding application, which enables Liberate Bio to streamline the screening of lipid nanoparticle delivery systems in living organisms. Rather than relying on conventional methods that demand sophisticated equipment and technical expertise, this approach delivers a straightforward assessment of delivery efficiency and translation performance. The result: researchers can accomplish what previously required extensive resources and time in a fraction of the effort.

Platinum’s core strength lies in its capacity to achieve single-amino acid resolution when characterizing protein sequences and variations. This granular level of precision allows researchers to tag, track, select, and quantify target proteins simultaneously—a capability applicable across both laboratory and in-vivo research environments.

Why This Approach Stands Apart

Traditional protein analysis methods, particularly mass spectrometry, impose substantial barriers to adoption. The Platinum system removes these obstacles by eliminating the need for expensive instrumentation and specialized technical knowledge. Liberate Bio’s experience validates this advantage: the integration has already demonstrated measurable improvements in their discovery workflows.

Industry Implications and Market Impact

According to Walter Strapps, Chief Scientific Officer at Liberate Bio, “The incorporation of Platinum’s barcoding functionality into our workflow represents a meaningful advancement. We’re now able to compress our discovery and screening timelines while reducing operational costs. This positions us to expand the frontiers of what targeted genetic therapeutics can achieve.”

For Quantum-Si, this application exemplifies the broader potential of NGPS technology. Jeff Hawkins, CEO of Quantum-Si, highlighted the significance: “Protein barcoding is fundamentally changing how researchers approach therapeutic discovery. Liberate Bio’s successful deployment shows how this platform unlocks novel pathways in drug development, accelerating progress across the biotech sector.”

The collaboration underscores a growing recognition within pharmaceutical and biotech industries that next-generation protein sequencing is becoming indispensable for gene therapy innovation and accelerated drug discovery pipelines.

About the Companies

Liberate Bio focuses on leveraging advanced technologies to develop precision-targeted therapeutics addressing unmet clinical needs. The company specializes in engineering improved delivery mechanisms for genetic medicines, combining innovation with scientific rigor to advance the field of genetic therapeutics.

Quantum-Si Incorporated (Nasdaq: QSI) operates at the forefront of proteomics innovation. The company’s semiconductor-based platform enables single-molecule protein sequencing at scale, converting proteomic research into a digitized, data-driven discipline that propels drug discovery and diagnostic development beyond the capabilities of DNA sequencing alone.